Trump Announces Deal to Cut Obesity Drug Prices and Expand Medicare Coverage
TL;DR
Eli Lilly and Novo Nordisk have reached deals with the Trump administration to lower prices for their weight-loss drugs like Zepbound and Wegovy, making them more accessible to Medicare patients and receiving tariff relief, with the aim of expanding access and reducing costs for millions of Americans.
- Lilly, Novo to Lower Obesity Drug Prices in Trump Deal Bloomberg.com
- President Trump Makes an Announcement C-SPAN
- Certain obesity drugs will cost as little as $149 and Medicare will start covering them under White House deals CNN
- Trump strikes deal to lower cost of Wegovy, Zepbound weight loss drugs NBC News
- Trump punches new $35 billion hole in national debt with deal for Medicare to cover your Ozempic Fortune
Want the full story? Read the original reporting
Read on Bloomberg.com